{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:36:25Z","timestamp":1793885785019,"version":"4.8.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Relapse after remission remains the primary cause of treatment failure in acute myeloid leukemia (AML), underscoring the need for strategies to eliminate residual leukemic cells. The bone marrow (BM) microenvironment, largely orchestrated by the CXC chemokine receptor 4 (CXCR4)\u2013CXC motif chemokine 12 axis (CXCL12), enables leukemia cell survival and chemoresistance by anchoring blasts in their protective BM niche. Motixafortide, a selective CXCR4 antagonist, mobilizes leukemic cells and disrupts tumor microenvironment interactions in preclinical models. In this randomized, double-blind, placebo-controlled phase 2 trial, 128 patients in first remission received high-dose cytarabine plus motixafortide or placebo. Median relapse-free survival did not substantially differ between groups: 10.3 months (95% confidence interval [CI], 8.0-12.0) for motixafortide and 11.5 months (95% CI, 8.6-24.1) for placebo (log-rank P = .98). But single-cell measurable residual disease (scMRD) analysis, performed before consolidation, demonstrated heterogeneity of CXCR4 inhibition benefit; in the placebo group, higher CXCR4 expression was associated with increased relapse risk (P = .02), whereas in the motixafortide group, higher CXCR4 expression was linked to a reduced relapse rate (P = .047). Exploratory analyses identified scMRD levels at which higher MRD burden was associated with inferior overall survival. Taken together, combining functional MRD profiling with biomarker-driven patient selection, such as CXCR4 expression, may enable more precise and effective postremission interventions in AML. This trial was registered at www.clinicaltrials.gov as NCT02502968 and at EudraCT as 2014-002702-21.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032033","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:12:21Z","timestamp":1776186741000},"page":"545-559","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9646-9967","authenticated-orcid":false,"given":"Enise","family":"Ceran","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"},{"name":"3National Center for Tumor Diseases Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-3070","authenticated-orcid":false,"given":"Sonia","family":"Jaramillo Segura","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"},{"name":"3National Center for Tumor Diseases Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4545-124X","authenticated-orcid":false,"given":"Anne Kathrin","family":"Merbach","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6778-5971","authenticated-orcid":false,"given":"Christian","family":"Rohde","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxi","family":"Wass","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-4049","authenticated-orcid":false,"given":"Judith","family":"Schaffrath","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Durruthy-Durruthy","sequence":"additional","affiliation":[{"name":"5Mission Bio, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Arribas-Layton","sequence":"additional","affiliation":[{"name":"5Mission Bio, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-4449","authenticated-orcid":false,"given":"Adam","family":"Sciambi","sequence":"additional","affiliation":[{"name":"5Mission Bio, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-8581","authenticated-orcid":false,"given":"Kathrin","family":"Rieger","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nogai","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"7Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[{"name":"7Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":false,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, University Hospital Carl Gustav Carus and Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"},{"name":"3National Center for Tumor Diseases Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-1767","authenticated-orcid":false,"given":"Michelle","family":"Lotze","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Noppeney","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Medizinische Klinik I, Krankenhaus der Barmherzigen Br\u00fcder, Trier, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-2535","authenticated-orcid":false,"given":"Christian","family":"Brandts","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Hematology\/Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Krug","sequence":"additional","affiliation":[{"name":"13German Bone Marrow Donor Collection Center, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-8002","authenticated-orcid":false,"given":"Katharina S.","family":"G\u00f6tze","sequence":"additional","affiliation":[{"name":"14Department of Medicine III, Technical University Munich School of Medicine and Public Health, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Buske","sequence":"additional","affiliation":[{"name":"15Department of Medicine II, Community Hospital Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Florsch\u00fctz","sequence":"additional","affiliation":[{"name":"16Department of Oncology, City Hospital Dessau, Dessau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schubert","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine II, Elbland Hospital Riesa, Riesa, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Opitz","sequence":"additional","affiliation":[{"name":"18Department of Hematology and Oncology, Hospital St Elisabeth and St Barbara Halle, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"E\u00dfeling","sequence":"additional","affiliation":[{"name":"19Department of Medicine A, Hematology, Oncology, and Respiratory Medicine, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Witzendorff","sequence":"additional","affiliation":[{"name":"20Department of Hematology\/Oncology and Palliative Medicine, Evangelisches Stift St Martin, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"21Department of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Oncology and Palliative Medicine, Robert Bosch Hospital, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frickhofen","sequence":"additional","affiliation":[{"name":"23Department of Internal Medicine III, Dr Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[{"name":"24Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[{"name":"25Department of Internal Medicine 5, Oncology, Hematology and Bone Marrow Transplantation, Klinikum N\u00fcrnberg Campus Nord, Paracelsus Medical University, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Kunzmann","sequence":"additional","affiliation":[{"name":"26Department of Internal Medicine II, Medical Oncology, Comprehensive Cancer Center Mainfranken W\u00fcrzburg, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-6945","authenticated-orcid":false,"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[{"name":"27Department of Hematology and Oncology, Medical University Lausitz\u2013Carl Thiem, Cottbus, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Sayer","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Oncology, and Stem Cell Transplantation, Helios Klinikum Erfurt, University Campus of the Health and Medical University Erfurt, Erfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rank","sequence":"additional","affiliation":[{"name":"29Department of Internal Medicine II, University Hospital Augsburg, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hemmati","sequence":"additional","affiliation":[{"name":"30Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charit\u00e9 University Medical School, Potsdam, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Sch\u00fcler","sequence":"additional","affiliation":[{"name":"31Department of Internal Medicine, Hematology and Oncology, KMG Klinikum Luckenwalde, Luckenwalde, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-0831","authenticated-orcid":false,"given":"Marina","family":"Scheller","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Kowoll","sequence":"additional","affiliation":[{"name":"32Coordination Center for Clinical Trials, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Steighardt","sequence":"additional","affiliation":[{"name":"32Coordination Center for Clinical Trials, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayram","family":"Edemir","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-4921","authenticated-orcid":false,"given":"Beatrice","family":"Ludwig-Kraus","sequence":"additional","affiliation":[{"name":"33Department of Laboratory Medicine, Central Laboratory, University Hospital Halle, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz P.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Edemir","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Vainstein-Haras","sequence":"additional","affiliation":[{"name":"34BioLineRx Ltd, Modi'in, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Sorani","sequence":"additional","affiliation":[{"name":"34BioLineRx Ltd, Modi'in, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Glicko-Kabir","sequence":"additional","affiliation":[{"name":"34BioLineRx Ltd, Modi'in, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaul","family":"Kadosh","sequence":"additional","affiliation":[{"name":"34BioLineRx Ltd, Modi'in, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Tavor","sequence":"additional","affiliation":[{"name":"35Department of Hematology, Assuta Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Gromann","sequence":"additional","affiliation":[{"name":"32Coordination Center for Clinical Trials, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-2586","authenticated-orcid":false,"given":"Andreas","family":"Wienke","sequence":"additional","affiliation":[{"name":"36Institute of Medical Epidemiology, Biometrics and Informatics, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bauer","sequence":"additional","affiliation":[{"name":"37Institute of Pathology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-5575","authenticated-orcid":false,"given":"Claudia","family":"Wickenhauser","sequence":"additional","affiliation":[{"name":"37Institute of Pathology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, University Hospital Carl Gustav Carus and Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"38Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-3536","authenticated-orcid":false,"given":"Adelheid","family":"Cerwenka","sequence":"additional","affiliation":[{"name":"39Mannheim Institute for Innate Immunoscience, Department of Immunobiochemistry, Medical Faculty Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-5516","authenticated-orcid":false,"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Hematology\/Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-3029","authenticated-orcid":false,"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, University Hospital Carl Gustav Carus and Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-777X","authenticated-orcid":false,"given":"Christian","family":"Junghan\u00df","sequence":"additional","affiliation":[{"name":"40Department of Medicine, Clinic II, Hematology, Oncology, and Palliative Care, Rostock University Medical Centre, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Medical Faculty, University of Heidelberg, Heidelberg, Germany"},{"name":"3National Center for Tumor Diseases Heidelberg, Heidelberg, Germany"},{"name":"4Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026073011321963600_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026073011321963600_bib2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"2026073011321963600_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2026073011321963600_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026073011321963600_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/ehm.11.30","article-title":"The bone marrow microenvironment and leukemia: biology and therapeutic targeting","volume":"4","author":"Sison","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"2026073011321963600_bib6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2026073011321963600_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3904\/kjim.2016.244","article-title":"Targeting the CXCL12\/CXCR4 axis in acute myeloid leukemia: from bench to bedside","volume":"32","author":"Cho","year":"2017","journal-title":"Korean J Intern Med"},{"issue":"1","key":"2026073011321963600_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7150\/thno.5150","article-title":"Role of CXCR4 in the pathogenesis of acute myeloid leukemia","volume":"3","author":"Peled","year":"2013","journal-title":"Theranostics"},{"issue":"2","key":"2026073011321963600_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/leu.2008.182","article-title":"Combining SDF-1\/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia","volume":"23","author":"Fierro","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"2026073011321963600_bib10","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2026073011321963600_bib11","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI66553","article-title":"CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"2026073011321963600_bib12","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/1078-0432.CCR-15-2618","article-title":"The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4\/CXCL12 pathway","volume":"23","author":"Beider","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2026073011321963600_bib13","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2017.82","article-title":"The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a\/16-1 expression","volume":"31","author":"Abraham","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2026073011321963600_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjh.14075","article-title":"Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia","volume":"174","author":"Randhawa","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"2026073011321963600_bib15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.33338","article-title":"BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed\/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"2026073011321963600_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11899-017-0419-5","article-title":"Methods of detection of measurable residual disease in AML","volume":"12","author":"Zhou","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2026073011321963600_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nri.2016.56","article-title":"Computational flow cytometry: helping to make sense of high-dimensional immunology data","volume":"16","author":"Saeys","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2026073011321963600_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat Methods"},{"issue":"38","key":"2026073011321963600_bib19","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci Adv"},{"issue":"7834","key":"2026073011321963600_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"2","key":"2026073011321963600_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput Stat Data Anal"},{"issue":"26","key":"2026073011321963600_bib22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2026073011321963600_bib23","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2026073011321963600_bib24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.22510","article-title":"Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype","volume":"109","author":"Konoplev","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2026073011321963600_bib25","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026073011321963600_bib26","article-title":"Association of CXCR4 expression and clinical outcome in different subsets of de novo acute myeloid leukemia patients","volume":"66","author":"Rady","year":"2020","journal-title":"Clin Lab"},{"issue":"9","key":"2026073011321963600_bib27","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1634\/stemcells.2007-0161","article-title":"Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003","volume":"25","author":"Abraham","year":"2007","journal-title":"Stem Cells"},{"issue":"8","key":"2026073011321963600_bib28","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-03-3693","article-title":"CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice","volume":"64","author":"Tavor","year":"2004","journal-title":"Cancer Res"},{"issue":"24","key":"2026073011321963600_bib29","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"17","key":"2026073011321963600_bib30","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2026073011321963600_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","article-title":"In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia","volume":"117","author":"Galmarini","year":"2002","journal-title":"Br J Haematol"},{"issue":"9","key":"2026073011321963600_bib32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026073011321963600_bib33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00277-015-2442-8","article-title":"VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia","volume":"94","author":"Bae","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"2026073011321963600_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0301-472X(03)00066-3","article-title":"The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation","volume":"31","author":"Cignetti","year":"2003","journal-title":"Exp Hematol"},{"issue":"15","key":"2026073011321963600_bib35","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1002\/cam4.2535","article-title":"Prognostic significance of CXCR4 expression in acute myeloid leukemia","volume":"8","author":"Du","year":"2019","journal-title":"Cancer Med"},{"issue":"13","key":"2026073011321963600_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018  29","journal-title":"N Engl J Med"},{"issue":"1","key":"2026073011321963600_bib37","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41467-021-21650-1","article-title":"Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics","volume":"12","author":"Velten","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"2026073011321963600_bib38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2026073011321963600_bib39","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/5\/545\/2535843\/blood_bld-2025-032033-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/5\/545\/2535843\/blood_bld-2025-032033-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:32:29Z","timestamp":1785425549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/5\/545\/567755\/Inhibition-of-high-CXCR4-with-motixafortide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032033","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,30]]},"published":{"date-parts":[[2026,7,30]]}}}